Neurocrine Biosciences (NASDAQ:NBIX) Given Buy Rating at Guggenheim

Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “buy” rating reaffirmed by Guggenheim in a note issued to investors on Wednesday,Benzinga reports. They currently have a $175.00 price target on the stock. Guggenheim’s price objective would indicate a potential upside of 21.33% from the company’s current price.

Several other equities research analysts have also recently weighed in on the stock. Piper Sandler upped their price target on shares of Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a research report on Wednesday. Needham & Company LLC reiterated a “buy” rating and set a $185.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, April 6th. Citigroup boosted their price objective on shares of Neurocrine Biosciences from $204.00 to $242.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. HC Wainwright boosted their price objective on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Finally, Canaccord Genuity Group boosted their price objective on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $182.35.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX traded up $9.18 on Wednesday, reaching $144.24. 848,705 shares of the stock traded hands, compared to its average volume of 1,145,246. The company has a fifty day moving average price of $130.37 and a 200-day moving average price of $137.72. The company has a market cap of $14.51 billion, a price-to-earnings ratio of 31.02, a PEG ratio of 0.67 and a beta of 0.34. Neurocrine Biosciences has a 12 month low of $115.66 and a 12 month high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The business had revenue of $805.50 million during the quarter, compared to analysts’ expectations of $804.21 million. During the same period in the previous year, the company posted $1.69 EPS. Neurocrine Biosciences’s revenue for the quarter was up 28.3% on a year-over-year basis. As a group, research analysts anticipate that Neurocrine Biosciences will post 6.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Neurocrine Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NBIX. Gallacher Capital Management LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at about $232,000. Aware Super Pty Ltd as trustee of Aware Super acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at about $18,020,000. State of Michigan Retirement System raised its position in shares of Neurocrine Biosciences by 2.5% in the first quarter. State of Michigan Retirement System now owns 24,181 shares of the company’s stock valued at $3,186,000 after buying an additional 600 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Neurocrine Biosciences by 5.2% in the first quarter. Principal Financial Group Inc. now owns 238,161 shares of the company’s stock valued at $31,375,000 after buying an additional 11,784 shares during the last quarter. Finally, Chicago Partners Investment Group LLC raised its position in shares of Neurocrine Biosciences by 37.9% in the first quarter. Chicago Partners Investment Group LLC now owns 7,389 shares of the company’s stock valued at $969,000 after buying an additional 2,030 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Wedbush raised its price target on NBIX to $176 and kept an “outperform” rating, implying meaningful upside and likely supporting buy-side interest. Benzinga
• Positive Sentiment: Q1 results beat expectations: EPS and revenue topped consensus, net product sales rose ~44% YoY to roughly $811M, and management reaffirmed full-year INGREZZA sales guidance of $2.7–$2.8B — data that directly support valuation and near-term cash flow visibility. Q1 Press Release
• Positive Sentiment: INGREZZA sales were a key driver of the better-than-expected quarter, cited by multiple outlets — supporting the commercial growth story and analyst upgrades. Investing.com
• Positive Sentiment: Publication of expert recommendations for glucocorticoid dose reduction after initiating CRENESSITY (crinecerfont) — published in a peer-reviewed journal — should help clinicians reduce steroid burden in CAH patients and may accelerate real-world adoption. PR Newswire – CRENESSITY publication
• Positive Sentiment: Neurocrine announced a definitive agreement to acquire Soleno Therapeutics (including VYKAT XR for hyperphagia in Prader?Willi), expanding the company’s pipeline and near-term commercial opportunities; expected close in Q2 2026. Acquisition announcement
• Neutral Sentiment: Pipeline progress: initiation of a Phase 2 study of NBI-1117570 (M1/M4 agonist) in schizophrenia — a positive clinical update but earlier-stage and longer horizon for value realization. Seeking Alpha – presentation
• Neutral Sentiment: Analyst/market coverage and events: company to present at the Bank of America Health Care Conference (May 12) and several earnings call transcripts/analyst notes are circulating — useful for deeper due diligence but not immediate catalysts. Conference notice

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.